全文获取类型
收费全文 | 348462篇 |
免费 | 21262篇 |
国内免费 | 667篇 |
专业分类
耳鼻咽喉 | 4724篇 |
儿科学 | 12182篇 |
妇产科学 | 11595篇 |
基础医学 | 52859篇 |
口腔科学 | 8279篇 |
临床医学 | 29243篇 |
内科学 | 67701篇 |
皮肤病学 | 7477篇 |
神经病学 | 26812篇 |
特种医学 | 12710篇 |
外国民族医学 | 43篇 |
外科学 | 50930篇 |
综合类 | 8059篇 |
现状与发展 | 2篇 |
一般理论 | 201篇 |
预防医学 | 24853篇 |
眼科学 | 7802篇 |
药学 | 24881篇 |
中国医学 | 921篇 |
肿瘤学 | 19117篇 |
出版年
2021年 | 4596篇 |
2020年 | 2739篇 |
2019年 | 4004篇 |
2018年 | 5553篇 |
2017年 | 4216篇 |
2016年 | 4789篇 |
2015年 | 5357篇 |
2014年 | 7009篇 |
2013年 | 10253篇 |
2012年 | 13547篇 |
2011年 | 13926篇 |
2010年 | 8495篇 |
2009年 | 7578篇 |
2008年 | 12061篇 |
2007年 | 12904篇 |
2006年 | 12419篇 |
2005年 | 11740篇 |
2004年 | 11244篇 |
2003年 | 10460篇 |
2002年 | 9836篇 |
2001年 | 13554篇 |
2000年 | 13827篇 |
1999年 | 11667篇 |
1998年 | 3356篇 |
1997年 | 3070篇 |
1996年 | 2826篇 |
1995年 | 2727篇 |
1992年 | 8408篇 |
1991年 | 8532篇 |
1990年 | 8323篇 |
1989年 | 8150篇 |
1988年 | 7384篇 |
1987年 | 7134篇 |
1986年 | 6777篇 |
1985年 | 6573篇 |
1984年 | 4843篇 |
1983年 | 4185篇 |
1982年 | 2546篇 |
1979年 | 4456篇 |
1978年 | 3260篇 |
1977年 | 2765篇 |
1976年 | 2528篇 |
1975年 | 2852篇 |
1974年 | 3370篇 |
1973年 | 3380篇 |
1972年 | 3130篇 |
1971年 | 2957篇 |
1970年 | 2845篇 |
1969年 | 2590篇 |
1968年 | 2549篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
Michels Guido Horn Rudolf Helfen Andreas Hagendorff Andreas Jung Christian Hoffmann Beatrice Jaspers Natalie Kinkel Horst Greim Clemens-Alexander Knebel Fabian Bauersachs Johann Busch Hans-Jörg Kiefl Daniel Spiel Alexander O. Marx Gernot Dietrich Christoph F. 《Der Anaesthesist》2022,71(4):307-310
Die Anaesthesiologie - 相似文献
2.
Journal of Behavioral Medicine - Evidence supports the use of graphic warnings to educate the public about the health harms of smoking and suggests warnings eliciting negative emotional responses... 相似文献
3.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
4.
Forgiveness has been found one substantial element in the recovery for women survivors from intimate partner violence following the termination of the abusive relationship. To further investigate the details of forgiveness in this specific context, the present study explored the process of forgiveness using grounded theory. In-depth and semi-structured interviews were conducted with 25 Chinese women survivors of IPV. The findings suggest that forgiveness is a strength-based process including empowerment, transformation, and integration phases. In the empowerment phase, survivors obtain strength at the intrapersonal, behavioural, and interpersonal levels. In the transformation phase, survivors complete cognitive transformation for their IPV experiences and emotional transformation towards former partners. In the integration phase, survivors—now freed from the past—reflect upon and apply the changes they have undergone. Two trajectories in the process were found. One trajectory is going through stages sequentially and the other trajectory is experiencing back and forth between empowerment and transformation stages before moving into the integration stage. The study's findings broaden our knowledge of the strength-based forgiveness process that women survivors of IPV undergo during recovery. Practitioners and policymakers could develop programmes and policies that support forgiveness by holistically facilitating their recovery and empowerment like assistance in dealing with life difficulties and promoting their reconnection with social networks. To improve the transferability and validity of the findings, the forgiveness of survivors of IPV could be explored in a diverse sample (e.g., survivors with low educational background or live in the rural area). 相似文献
5.
6.
7.
8.
9.